A STING agonist peptide conjugate and its application
By designing STING agonist peptide conjugates and utilizing the responsiveness of the target peptide and tumor microenvironment, targeted delivery and precise release of STING agonists can be achieved, solving the problem of targeted activation and release of drugs in tumors and improving treatment efficiency and safety.
Patent Information
- Application Number
- CN202610149440.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2026-02-03
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2046-02-03
AI Technical Summary
The existing STING agonists have difficulty achieving targeted activation and precise release in tumors, resulting in insufficient efficacy and severe side effects, which limits their clinical application.
We designed STING agonist peptide conjugates, introduced target peptides through functionalization, constructed responsive peptide conjugates, and utilized biomarkers in the tumor microenvironment to achieve targeted drug delivery and precise release.
To improve the efficiency of drug treatment, reduce toxic side effects, achieve a balance between synergistic effect and toxicity reduction, and enhance the targeting and bioavailability of tumor tissue.
Smart Images

Figure CN122182796B_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of peptide-conjugated drug technology, specifically relating to a STING agonist peptide conjugate and its applications. Background Technology
[0002] STING (stimulator of interferon genes), a key signal transduction molecule involved in the innate immune response, plays a vital role in inducing the secretion of type I interferon and pro-inflammatory cytokines, defending against viral and intracellular bacterial infections, and regulating spontaneous anti-tumor immune responses in vivo. Activation of the STING signaling pathway can induce the production of type I interferon and cytokines, thereby promoting the recruitment and activation of effector T cells that specifically kill tumor cells. This enables them to exert their effector function and kill tumor cells, transforming "cold" tumors into "hot" tumors, enhancing the body's response to tumor immunotherapy, and achieving anti-tumor immunotherapy. Therefore, the development of STING agonists is a research hotspot in the field of tumor immunology.
[0003] Currently, several STING agonists are in clinical and preclinical studies. STING agonists are mainly divided into two categories: nucleotides and non-nucleotides. Nucleotide STING agonists are primarily natural cyclic dinucleotides and their analogues. However, due to their relatively large molecular weight, strong negative charge, high polarity, and the ease with which their phosphodiester bonds are hydrolyzed by enzymes, they exhibit insufficient pharmacokinetic activity and low bioavailability, severely limiting their clinical application. While non-nucleotide STING agonists show better pharmacokinetics and stability, the widespread expression of STING in tumors and normal tissues leads to side effects such as non-targeted activation and systemic cytokine storms, making the clinical translation of STING agonists a significant challenge.
[0004] Therefore, achieving targeted activation and precise release of STING agonists in tumors is crucial for improving efficacy and reducing side effects. Summary of the Invention
[0005] To address the challenge of achieving targeted activation and precise release of STING agonists in tumors using existing technologies, this application functionalizes STING agonists and introduces targeting peptides to construct responsive STING agonist peptide conjugates with targeting functionality. This enables targeted delivery and precise release of STING agonists at the lesion site, thereby improving therapeutic efficiency and bioavailability, reducing toxic side effects, broadening the safety window, and achieving a balance between efficacy and safety. The survival rate of breast cancer cells treated with the STING agonist peptide conjugate designed in this invention can be as low as 10% and not exceed 32%.
[0006] Targeting peptides can deliver drugs to tumor sites in a directed manner, enhancing their anti-tumor efficacy and reducing their toxic side effects. The unique pathological characteristics of the tumor microenvironment (TME) not only provide a molecular basis for targeted recognition, but its special biochemical environment also creates favorable conditions for responsive drug release. By utilizing biomarkers specifically highly expressed in the TME, such as matrix metalloproteinase 2 (MMP2) and cathepsins (CTS), intelligent responsive drug delivery systems can be constructed, enabling drugs to be released on demand at the target site, thereby significantly improving drug bioavailability and therapeutic efficiency, and facilitating precision cancer treatment.
[0007] However, peptides are extremely unstable under non-physiological conditions, easily undergoing denaturation, aggregation, or precipitation. They are particularly prone to losing their native conformation in organic solvents, leading to a significant decrease in solubility and making reaction conditions incompatible with peptide stability. Furthermore, peptides are susceptible to racemization during synthesis or modification—especially at the C-terminus or sites involving chiral centers—potentially initiating racemization and thus destroying their inherent biological activity. In acidic or alkaline environments, peptides may also experience peptide bond hydrolysis, premature loss of side-chain protecting groups, and other unintended chemical modifications as side reactions. Certain amino acid residues sensitive to reaction conditions (such as methionine and cysteine) are also highly susceptible to oxidation or degradation during processing.
[0008] Furthermore, polypeptide chains contain a large number of reactive functional groups derived from amino acid side chains (such as amino, carboxyl, hydroxyl, thiol, guanidine, etc.), which are diverse in type and chemical properties, making them far more complex than typical small molecules. The STING agonist-peptide conjugates described in this invention require the selective attachment of small molecule drugs to specific sites on the polypeptide chain, while avoiding non-specific side reactions with numerous other structurally similar or reactive functional groups. Simultaneously, during the coupling reaction, it is also necessary to maintain the conformation and biological activity of the polypeptide, preventing the inactivation or degradation of the coupled drug molecule.
[0009] This invention, through rational design, functionalizes STING agonists and conjugates them with tumor-targeting peptides and tumor microenvironment-responsive peptides to construct targeted and responsive STING agonist-peptide conjugates, potentially enabling precise drug delivery and controlled release at tumor sites. This strategy not only significantly enhances the therapeutic efficacy and bioavailability of STING agonists but also effectively reduces systemic toxicity and broadens the therapeutic safety window, thereby ensuring safety while enhancing efficacy and achieving an ideal balance of "enhanced efficacy and reduced toxicity."
[0010] Specifically, the scheme of this application is as follows: This application provides a STING agonist polypeptide conjugate with a PLSD structure; wherein, P is a polypeptide with tumor targeting properties and the number of amino acids is 3-10;
[0011] L is a linking group, including a connector or reactive group that can link to a peptide amino or peptide carboxyl group; L may or may not be present.
[0012] S is a spacer; S may or may not exist.
[0013] D is a STING agonist, with the following structural formula: Or, it may be an optical isomer, tautomer, hydrate, solvate, stable isotopic derivative, or pharmaceutically acceptable salt of the above-mentioned compounds;
[0014] R1, R2, R3, and R4 are each independently at least one of hydrogen, halogen, hydroxyl, amino, nitro, cyano, C1-C10 alkyl, C1-C10 haloalkyl, C1-C10 alkoxy, C2-C10 alkenyl, C2-C10 alkynyl, and C3-C9 cycloalkyl.
[0015] R5 and R6 are each independently at least one of hydrogen, halogen, C1-C10 alkyl, C1-C10 haloalkyl, C1-C6 alkoxy, C2-C10 alkenyl, C2-C10 alkynyl, and C3-C9 cycloalkyl;
[0016] R7 is selected from hydrogen, , , , At least one of them;
[0017] Wherein, Ra, Rb, Rc, and Rd are each independently at least one of hydrogen, C1-C20 alkyl, C1-C20 haloalkyl, C2-C20 alkenyl, C2-C20 alkynyl, C3-C9 cycloalkyl, C6-C10 aromatic, 5-10 heteroaryl, and 3-9 heterocyclic.
[0018] The aforementioned C1-C20 alkyl, C1-C20 haloalkyl, C2-C20 alkenyl, C2-C20 alkynyl, C2-C20 azide, C3-C9 cycloalkyl, C6-C10 aromatic, 5-10 heteroaryl, and 3-9 heterocyclic groups are each independently and optionally substituted with one or more halogens, hydroxyl groups, amino groups, nitro groups, cyano groups, C1-C20 alkyl, C1-C20 haloalkyl, C2-C20 alkenyl, C2-C20 alkynyl, C3-C9 cycloalkyl, C6-C10 aromatic, 5-10 heteroaryl, and 3-9 heterocyclic groups;
[0019] n = 0-50;
[0020] X is selected from oxygen or sulfur.
[0021] D can be... , , , , One of them.
[0022] Further, P includes at least one of cysteine, arginine, glycine, aspartic acid, lysine, proline, valine, leucine, isoleucine, phenylalanine, tryptophan, threonine, histidine, methionine, glutamic acid, serine, tyrosine, asparagine, glutamine, methionine, alanine, and histidine.
[0023] Furthermore, the chemical formula of L is shown in Formula I below.
[0024]
[0025] Formula I
[0026] Among them, E and F include linkers or reactive groups that can connect to peptide amino or peptide carboxyl groups;
[0027] Lc includes peptide residues, the number of amino acid residues constituting the peptide residues being 0-20, and the amino acid residues being optionally substituted by at least one C1-C10 alkyl substituent;
[0028] m1 and m2 are each independently selected from integers between 0 and 20.
[0029] Furthermore, S includes one of the following structures:
[0030] .
[0031] Furthermore, P is octreotide or a derivative thereof. Octreotide (FCFWKTCT) is a somatostatin analogue, belonging to the octapeptide cyclic compound family, which can precisely target the human somatostatin receptor 2 (SSTR2) receptor. Somatostatin receptor 2 is expressed in more than 80% of well-differentiated neuroendocrine tumors, thereby achieving the targeting of STING agonist-octreotide conjugate to tumor tissue.
[0032] Furthermore, P is iRGD, RGD, or a derivative of iRGD, RGD.
[0033] iRGD (c(CRGDKGPDC)) is a novel cyclic peptide composed of 9 amino acids. It specifically recognizes integrin αvβ3, which is highly expressed on the surface of tumor vascular endothelial cells, achieving tumor-targeting function. It has shown good effects in increasing the tumor penetration of anti-tumor drugs and reducing toxic side effects. The KGPD fragment in the iRGD sequence can be specifically cleaved by tumor-associated proteases, exposing the hidden CendR sequence. This sequence can bind to neuropilin-1 (NRP-1) on the surface of tumor cells, mediating iRGD penetration of the extracellular matrix of tumor tissue and deep into the tumor interior, thus achieving tumor penetration. The two characteristic domains, αvβ3 / 5 and CendR, can sequentially bind to tumor vascular endothelial cells, guiding the drug across the endothelial barrier via Neuropilin-1 (NRP-1), exhibiting good vascular affinity and penetration.
[0034] The main mechanism of action of the RGD sequence is its specific binding to integrin receptors. This allows drug carriers to be specifically enriched in tumor vascular endothelial cells and tumor cells that highly express integrins, increasing drug concentration at the target site, enhancing therapeutic efficacy, and reducing toxic side effects on normal tissues.
[0035] In some embodiments, the STING agonist polypeptide conjugate may be one of the structures (1)-(51) shown below.
[0036]
[0037] D1-4PEG-FCFWKTCT (1)
[0039]
[0040] D1-7PEG-FCFWKTCT (2)
[0042]
[0043] D1-Triazole-FCFWKTCT (3)
[0045]
[0046] D1-FCFWKTCT (4)
[0048]
[0049] D1-Triazole-7PEG-FCFWKTCT (5)
[0051]
[0052] D1-PVGLIG-4PEG-FCFWKTCT (6)
[0054]
[0055] D1-PVGLIG-7PEG-FCFWKTCT (7)
[0057]
[0058] D1- Triazole-PVGLIG-7PEG-FCFWKTCT (8)
[0060]
[0061] D1- Triazole-S1-PVGLIG-7PEG-FCFWKTCT (9)
[0063]
[0064] D1- Triazole-VC-7PEG-FCFWKTCT (10)
[0066]
[0067] D1-Triazole-GGFG-7PEG-FCFWKTCT (11)
[0069]
[0070] D1- Triazole-VA-7PEG-FCFWKTCT (12)
[0072]
[0073] D1- Triazole-EVC-7PEG-FCFWKTCT (13)
[0075]
[0076] D1- Triazole-SS-7PEG-FCFWKTCT (14)
[0078]
[0079] D1-hyd-7PEG-FCFWKTCT (15)
[0081]
[0082] D1-4PEG-RGD (16)
[0084]
[0085] D1-7PEG-RGD (17)
[0087]
[0088] D1-Triazole-RGD (18)
[0090]
[0091] D1-RGD (19)
[0093]
[0094] D1-Triazole-7PEG-RGD (20)
[0096]
[0097] D1-PVGLIG- 4PEG-RGD (21)
[0099]
[0100] D1-PVGLIG-7PEG-RGD (22)
[0102]
[0103] D1- Triazole-PVGLIG-7PEG-RGD (23)
[0105]
[0106] D1- Triazole-S1-PVGLIG-7PEG-RGD (24)
[0108]
[0109] D1- Triazole-VC-7PEG-RGD (25)
[0111]
[0112] D1-Triazole-GGFG-7PEG-RGD (26)
[0114]
[0115] D1- Triazole-VA-7PEG-RGD (27)
[0117]
[0118] D1- Triazole-EVC-7PEG-RGD (28)
[0120]
[0121] D1- Triazole-SS-7PEG-RGD (29)
[0123]
[0124] D1-hyd-7PEG-RGD (30)
[0126]
[0127] D1-4PEG-c(CRGDKGPDC) (31)
[0129]
[0130] D1-7PEG-c(CRGDKGPDC) (32)
[0132]
[0133] D1-Triazole-c(CRGDKGPDC) (33)
[0135]
[0136] D1-c(CRGDKGPDC) (34)
[0138]
[0139] D1-Triazole-7PEG-c(CRGDKGPDC) (35)
[0141]
[0142] D1-PVGLIG- 4PEG-c(CRGDKGPDC) (36)
[0144]
[0145] D1-PVGLIG-7PEG-c(CRGDKGPDC) (37)
[0147]
[0148] D1-Triazole-PVGLIG-4PEG-c(CRGDKGPDC) (38)
[0150]
[0151] D1- Triazole-S1-PVGLIG-7PEG-c(CRGDKGPDC) (39)
[0153]
[0154] D1- Triazole-VC-7PEG-c(CRGDKGPDC) (40)
[0156]
[0157] D1-Triazole-GGFG-4PEG-c(CRGDKGPDC) (41)
[0159]
[0160] D1- Triazole-VA-7PEG-c(CRGDKGPDC) (42)
[0162]
[0163] D1- Triazole-EVC-7PEG-c(CRGDKGPDC) (43)
[0165]
[0166] D1- Triazole-SS-7PEG-c(CRGDKGPDC) (44)
[0168]
[0169] D1-hyd-7PEG-c(CRGDKGPDC) (45)
[0171]
[0172] D2- Triazole-PVGLIG-7PEG-FCFWKTCT (46)
[0174]
[0175] D2- Triazole-PVGLIG-7PEG-RGD (47)
[0177]
[0178] D2- Triazole-PVGLIG-7PEG-c(CRGDKGPDC) (48)
[0180]
[0181] D3- Triazole-PVGLIG-7PEG-FCFWKTCT (49)
[0183]
[0184] D3- Triazole-PVGLIG-7PEG-RGD (50)
[0186]
[0187] D3- Triazole-PVGLIG-7PEG-c(CRGDKGPDC) (51)
[0189] This application also provides a pharmaceutical composition comprising the above-described STING agonist polypeptide conjugate and a pharmaceutically acceptable carrier.
[0190] This application also provides the use of the above-described STING agonist polypeptide conjugate or pharmaceutically acceptable salt or the above-described pharmaceutical composition in the preparation of a medicament for the prevention or treatment of STING-related diseases.
[0191] The STING-related diseases are selected from one or more of the following: gastrointestinal cancer, colorectal cancer, colon cancer, liver cancer, hepatocellular carcinoma, pancreatic cancer, biliary tract cancer, gastric cancer, genitourinary cancer, bladder cancer, testicular cancer, cervical cancer, malignant mesothelioma, osteosarcoma, esophageal cancer, laryngeal cancer, prostate cancer, hormone-resistant prostate cancer, lung cancer, small cell lung cancer, non-small cell lung cancer, breast cancer, triple-negative breast cancer, hematologic malignancies, leukemia, acute primitive lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, lymphoma, Hodgkin lymphoma, non-Hodgkin lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, ovarian cancer, brain cancer, neuroblastoma, Ewing sarcoma, renal cancer, epidermoid carcinoma, skin cancer, melanoma, multiple myeloma, and oral cancer.
[0192] The advantages of this invention are:
[0193] This invention combines a targeting peptide with a STING agonist through structural design, achieving targeted delivery and precise release of the STING agonist at the lesion site. This reduces drug loss during blood circulation, improves therapeutic efficiency and bioavailability, and reduces toxic side effects, thus achieving synergistic efficacy and reduced toxicity. The STING agonist peptide conjugate of this invention enhances the targeting of STING agonist drugs to tumor tissues and reduces toxic side effects on normal tissues. It represents a novel class of immune-stimulating conjugates, providing a new approach for tumor immunotherapy research.
[0194] The targeting peptides used in this invention have small molecular weights (typically <5 kDa). Compared to antibodies with similar targeting functions but larger molecular weights (~150 kDa), these peptides can more easily penetrate blood vessel walls, tissue barriers, and the tumor microenvironment, achieving a more uniform distribution and exhibiting excellent tumor tissue permeability, further improving therapeutic efficacy. Furthermore, compared to antibodies or protein-based targeted drugs, the targeting peptides used in this invention are biodegradable, therefore less likely to trigger an immune response, exhibiting low immunogenicity and good safety. Attached Figure Description
[0195] Figure 1 The results are for LC-MS of compound 38.
[0196] Figure 2The HPLC results for compound 38 are shown below. The lines of different colors represent chromatograms obtained using different detection wavelengths. The black line indicates a test wavelength of 214 nm, the blue line indicates a test wavelength of 280 nm, and the red line indicates a test wavelength of 254 nm.
[0197] Figure 3 The results are for LC-MS of compound 41.
[0198] Figure 4 The HPLC results for compound 41 are shown below. The lines of different colors represent chromatograms obtained using different detection wavelengths. The black line indicates a test wavelength of 214 nm, the blue line indicates a test wavelength of 280 nm, and the red line indicates a test wavelength of 254 nm.
[0199] Figure 5 This is the result of a security test. Detailed Implementation
[0200] The following examples are provided to further illustrate the present invention and are intended to explain the invention, not to limit its scope. Unless otherwise specified, all figures are expressed in parts by weight and weight percentages.
[0201] Unless otherwise specified, the raw materials used in this invention are all conventional commercially available products; unless otherwise specified, the methods used in this invention are all conventional methods in the field.
[0202] The embodiments of the present invention will be further described below with reference to several examples.
[0203] This invention relates to amino acid sequences. SEQ ID NO.1 is the sequence of iRGD, and the amino acid sequence is c(CRGDKGPDC). iRGD is a cyclic peptide, where c indicates cyclic closure. Its structure is cyclic by forming an intramolecular disulfide bond between two cysteine (Cys,C) residues at the N-terminus and C-terminus.
[0204] SEQ ID NO.2 is the sequence of octreotide, and the amino acid sequence is FCFWKTCT.
[0205] It should be understood that the described embodiments are merely some, not all, of the embodiments in this application. All other embodiments obtained by those skilled in the art based on the embodiments in this application without inventive effort are within the scope of protection of this application.
[0206] The terminology used in the embodiments of this application is for the purpose of describing particular embodiments only and is not intended to be limiting of this application. The singular forms “a,” “the,” and “the” used in the embodiments of this application and the appended claims are also intended to include the plural forms unless the context clearly indicates otherwise.
[0207] Depending on whether the linking to the polypeptide is achieved using a click reaction, the preparation method can be divided into two synthetic routes as shown in Examples 1 and 3.
[0208] Example 1
[0209] The synthesis route in this embodiment is shown below:
[0210] .
[0211] 1. Preparation of compound A:
[0212] In a 500 mL double-necked flask, compound SM1 (7 g, 29.4 mmol) was dissolved in N-methylpyrrolidone (100 mL), followed by the addition of silver carbonate (12.16 g, 44.1 mmol) and o-phenanthroline hydrate (582 mg, 2.94 mmol). The mixture was heated to 150 °C and reacted for 2 hours. After the reaction, the reaction solution was cooled to room temperature and filtered through diatomaceous earth. The filtrate was poured into 500 mL of water and extracted with 200 mL of ethyl acetate. The organic phases were combined, washed with water and saturated sodium chloride, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography to give compound A (4.8 g).
[0213] The NMR and high-resolution mass spectrometry data of compound A are as follows:
[0214] 1 H NMR (400 MHz, CDCl3) showed the following characteristic signals: δ 7.35 (s, 1H), 7.29 (d, J = 5.2 Hz, 1H), 7.25 (s, 1H), 7.19 (dd, J = 5.0, 0.8 Hz, 1H), 3.95 (s, 3H), 3.91 (s, 3H).
[0215] MALDI-TOF-HRMS showed the experimentally measured value as 217.0297 and C. 10 H 10 NaO2S [M + Na] + The theoretical value of 217.0299 is consistent.
[0216] The above spectroscopic data results show that compound A is consistent with the proposed structure.
[0217] 2. Preparation of compound B:
[0218] In a 100 mL two-necked flask, succinic anhydride (3.1 g, 30.9 mmol) and aluminum trichloride (2.7 g, 20.6 mmol) were dissolved in 10 mL of dichloromethane and stirred at 0 °C for 1 hour. Then, compound A (2.0 g, 10.3 mmol), dissolved in 40 mL of dichloromethane, was added dropwise to the above reaction solution over 30 minutes. The reaction mixture was then stirred overnight at 50 °C. The reaction mixture was poured into 100 mL of ice water, and the pH of the solution was adjusted to 10 with sodium hydroxide. The mixture was filtered to obtain a filtrate, which was further acidified with concentrated hydrochloric acid to a pH of 2, resulting in a solid precipitate. The precipitate was collected by filtration and washed with water and dichloromethane to obtain compound B (2.9 g).
[0219] The NMR and high-resolution mass spectrometry data of compound B are as follows:
[0220] 1 H NMR (400 MHz, DMSO-d6) showed the following characteristic signals: δ 12.27 (s, 1H), 8.19 (s, 1H), 7.58 (s, 1H), 7.51 (s, 1H), 3.83 (d, J = 10.4 Hz, 6H), 3.25 (t, J = 6.2 Hz, 2H), 2.63 (t, J = 6.2 Hz, 2H).
[0221] MALDI-TOF-HRMS showed the experimentally measured value as 317.0462 and C. 14 H 14 NaO5S[M + Na] + The theoretical calculated value of 317.0460 is consistent.
[0222] The above spectroscopic data results show that compound B is consistent with the proposed structure.
[0223] 3. Preparation of compound C:
[0224] Compound B (0.59 g, 2.0 mmol), 50 mL of dichloromethane, compound SM2 (1.06 g, 4.0 mmol), and DCC (0.83 g, 4.0 mmol) were added sequentially to a 100 mL double-necked flask. After reacting at room temperature for 12 hours, the filtrate was poured into 50 mL of water and extracted with 50 mL of dichloromethane. The organic phases were combined, washed with water and saturated sodium chloride, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography to obtain compound C (0.75 g).
[0225] The NMR and high-resolution mass spectrometry data of compound C are as follows:
[0226] The 1H NMR (400 MHz, CDCl3) showed the following characteristic signals: δ 8.27 (s, 1H), 7.58 (s, 1H), 7.51 (s, 1H), 4.22–4.03 (m, 2H), 3.83 (d, J = 10.4 Hz, 6H), 3.25 (t, J = 6.2 Hz, 2H), 3.21–3.01 (m, 16H), 2.63 (t, J = 6.2 Hz, 2H), 2.25 (t, J = 5.6 Hz, 2H).
[0227] MALDI-TOF-HRMS showed an experimentally measured value of 577.1723 and the relationship between C25H34NaO11S [M + Na] + The theoretical value of 577.1720 is consistent.
[0228] The above spectroscopic data results show that compound C is consistent with the proposed structure.
[0229] 4. Preparation of compound D:
[0230] In a 100 mL double-necked flask, compound C (0.54 g, 1.0 mmol) and 10 mL of diDMF were added and stirred until homogeneous. Then, HATU (0.38 g, 1.0 mmol) and HOSU (0.12 g, 1.0 mmol) were added. After reacting at room temperature for 2 hours, ethyl acetate was added. The organic phase was washed twice with saturated sodium chloride, dried with anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography to obtain compound D (0.52 g).
[0231] The NMR and high-resolution mass spectrometry data of compound D are as follows:
[0232] The 1H NMR (400 MHz, CDCl3) results show the following characteristic signals: δ 8.30 (s, 1H), 7.61 (s, 1H), 7.53 (s, 1H), 4.31–4.08 (m, 2H), 3.85 (d, J = 10.2 Hz, 6H), 3.32 (t, J = 4.4 Hz, 2H), 3.18–3.04 (m, 16H), 2.87–2.79 (m, 4H), 2.55 (t, J = 6.0 Hz, 2H), 2.28 (t, J = 5.2 Hz, 2H).
[0233] MALDI-TOF-HRMS showed an experimentally measured value of 644.2022 and C. 29 H 37 NNaO 13 S [M + Na] + The theoretical calculation value of 644.2024 is consistent.
[0234] 5. In a 50 mL double-necked flask, compound D (0.13 g, 0.2 mmol) was dissolved in 5 mL of DMF. Compound SM3 (0.21 g, 0.2 mmol) and DIPEA (77 mg, 0.6 mmol) were added. After reacting at room temperature for 2 hours, the sample was sent for preparative chromatography to obtain the target molecule compound 1 (0.15 g). LC-MS m / z: 1573.6 (M + H) + .
[0235] Example 2
[0236] Compounds 2, 4, 6, 7, 16-19, 21, 22, 31, 32, 34, 36, and 37 were prepared using adapted polypeptides (as described in the preparations or as obtained from commercial sources) according to the procedure outlined in Example 1.
[0237] The chemical formula is shown below:
[0238]
[0239] D1-7PEG-FCFWKTCT (2)
[0241]
[0242] D1-FCFWKTCT (4)
[0244]
[0245] D1-PVGLIG-4PEG-FCFWKTCT (6)
[0247]
[0248] D1-PVGLIG-7PEG-FCFWKTCT (7)
[0250]
[0251] D1-4PEG-RGD (16)
[0253]
[0254] D1-7PEG-RGD (17)
[0256]
[0257] D1-Triazole-RGD (18)
[0259]
[0260] D1-RGD (19)
[0262]
[0263] D1-PVGLIG- 4PEG-RGD (21)
[0265]
[0266] D1-PVGLIG-7PEG-RGD (22)
[0268]
[0269] D1-4PEG-c(CRGDKGPDC) (31)
[0271]
[0272] D1-7PEG-c(CRGDKGPDC) (32)
[0274]
[0275] D1-c(CRGDKGPDC) (34)
[0277]
[0278] D1-PVGLIG- 4PEG-c(CRGDKGPDC) (36)
[0280]
[0281] D1-PVGLIG-7PEG-c(CRGDKGPDC) (37)
[0283] Table 1. Relative molecular weights of compounds 2, 4, 6, 7, 16-19, 21, 22, 31, 32, 34, 36, and 37
[0284] Compound serial number <![CDATA[Relative molecular weight [M+H] + > 2 1705.6 4 1325.5 6 2223.0 7 2355.1 16 871.3 17 1003.4 19 623.2 21 1519.8 22 1652.8 31 1472.5 32 1604.6 34 1224.4 36 2120.9 37 2254.0
[0285] Example 3
[0286] The synthetic route for preparing compound 3 using click reaction is shown below. The specific preparation steps are described below.
[0287]
[0288] Preparation of compound D4:
[0289] Compound B (0.29 g, 1.0 mmol), 20 mL of dichloromethane, compound SM4 (0.19 g, 2.0 mmol), and DCC (0.42 g, 2.0 mmol) were added sequentially to a 100 mL double-necked flask. After reacting at room temperature for 12 hours, the filtrate was poured into 20 mL of water and extracted with 20 mL of dichloromethane. The organic phases were combined, washed with water and saturated sodium chloride, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography to obtain compound D4 (0.35 g).
[0290] The NMR and high-resolution mass spectrometry data of compound D4 are as follows:
[0291] The 1H NMR (400 MHz, CDCl3) results show the following characteristic signals: δ 8.28 (s, 1H), 7.60 (s, 1H), 7.49 (s, 1H), 4.18–4.05 (m, 2H), 3.92 (s, 3H), 3.85 (s, 3H), 3.43 (t, J = 5.6 Hz, 2H), 2.95 (s, 1H), 2.77 (t, J = 4.2 Hz, 2H), 2.32 (t, J = 5.2 Hz, 2H), 1.67–1.42 (m, 4H).
[0292] MALDI-TOF-HRMS displays [M + Na] + The experimentally measured value of 397.1084 and C 20 H 22 The theoretical calculated value of NaO5S, 397.1086, is consistent.
[0293] 2. In a 50 mL double-necked flask, compound D4 (74 mg, 0.2 mmol) was dissolved in 5 mL of DMF. Then, SM5 (215 mg, 0.2 mmol), CuSO4·5H2O (159 mg, 1.0 mmol), and TBTA (212 mg, 0.4 mmol) were added sequentially. After reacting at room temperature for 6 hours, the sample was sent for preparative chromatography to obtain the target molecule compound 3 (155 mg). LC-MS m / z: 1449.5 (M + H) + .
[0294] Example 4
[0295] Compounds 5, 8, 9, 10-15, 18, 20, 23-30, 33, 35, and 38-51 were prepared using adapted polypeptides (as described in the preparations or as obtained from commercial sources) according to a procedure similar to that outlined in Example 3 above.
[0296]
[0297] D1-Triazole-7PEG-FCFWKTCT (5)
[0299]
[0300] D1-Triazole-PVGLIG-7PEG-FCFWKTCT (8)
[0302]
[0303] D1-Triazole-S1-PVGLIG-7PEG-FCFWKTCT (9)
[0305]
[0306] D1-Triazole-VC-7PEG-FCFWKTCT (10)
[0308]
[0309] D1-Triazole-GGFG-7PEG-FCFWKTCT (11)
[0311]
[0312] D1-Triazole-VA-7PEG-FCFWKTCT (12)
[0314]
[0315] D1- Triazole-EVC-7PEG-FCFWKTCT (13)
[0317]
[0318] D1- Triazole-SS-7PEG-FCFWKTCT (14)
[0320]
[0321] D1-hyd-7PEG-FCFWKTCT (15)
[0323]
[0324] D1-Triazole-RGD (18)
[0326]
[0327] D1-Triazole-7PEG-RGD (20)
[0329]
[0330] D1- Triazole-PVGLIG-7PEG-RGD (23)
[0332]
[0333] D1- Triazole-S1-PVGLIG-7PEG-RGD (24)
[0335]
[0336] D1- Triazole-VC-7PEG-RGD (25)
[0338]
[0339] D1-Triazole-GGFG-7PEG-RGD (26)
[0341]
[0342] D1- Triazole-VA-7PEG-RGD (27)
[0344]
[0345] D1- Triazole-EVC-7PEG-RGD (28)
[0347]
[0348] D1- Triazole-SS-7PEG-RGD (29)
[0350]
[0351] D1-hyd-7PEG-RGD (30)
[0353]
[0354] D1-Triazole-c(CRGDKGPDC) (33)
[0356]
[0357] D1-Triazole-7PEG-c(CRGDKGPDC) (35)
[0359]
[0360] D1-Triazole-PVGLIG-4PEG-c(CRGDKGPDC) (38)
[0362]
[0363] D1- Triazole-S1-PVGLIG-7PEG-c(CRGDKGPDC) (39)
[0365]
[0366] D1- Triazole-VC-7PEG-c(CRGDKGPDC) (40)
[0368]
[0369] D1-Triazole-GGFG-4PEG-c(CRGDKGPDC) (41)
[0371]
[0372] D1- Triazole-VA-7PEG-c(CRGDKGPDC) (42)
[0374]
[0375] D1- Triazole-EVC-7PEG-c(CRGDKGPDC) (43)
[0377]
[0378] D1- Triazole-SS-7PEG-c(CRGDKGPDC) (44)
[0380]
[0381] D1-hyd-7PEG-c(CRGDKGPDC) (45)
[0383]
[0384] D2- Triazole-PVGLIG-7PEG-FCFWKTCT (46)
[0386]
[0387] D2- Triazole-PVGLIG-7PEG-RGD (47)
[0389]
[0390] D2- Triazole-PVGLIG-7PEG-c(CRGDKGPDC) (48)
[0392]
[0393] D3- Triazole-PVGLIG-7PEG-FCFWKTCT (49)
[0395]
[0396] D3-Triazole-PVGLIG-7PEG-RGD (50)
[0398]
[0399] D3- Triazole-PVGLIG-7PEG-c(CRGDKGPDC) (51)
[0401] Table 2. Relative molecular weights of target compounds 5, 8, 9, 10-15, 18, 20, 23-30, 33, 35, 38-51
[0402] compound <![CDATA[Relative molecular weight [M+H] + <!-- 36 -->]]> 5 1815.2 8 2464.8 9 2585.2 10 2184.6 11 2246.0 12 2098.4 13 2257.6 14 1908.3 15 1985.2 18 733.6 20 1112.5 23 1761.9 24 1883.1 25 1481.7 26 1543.7 27 1395.7 28 1554.8 29 1205.1 30 1282.6 33 1334.5 35 1713.7 38 2232.8 39 2484.1 40 2083.1 41 2014.0 42 1997.3 43 2157.4 44 1807.1 45 1884.8 46 2483.2 47 1781.2 48 2382.1 49 2572.1 50 1870.1 51 2470.1
[0403] according to Figure 1 and Figure 2 The results show that the LC-MS of compound 38 are correct and the HPLC purity is 97.15%.
[0404] according to Figure 3 and Figure 4 The results of LC-MS of compound 41 show that the compound has the correct structure and the HPLC purity is 95.52%.
[0405] Example 5 Activity Test
[0406] I. THP1-Dual™ Reporter Gene Activity Assay
[0407] The THP1-Dual used in the test TM (InvivoGen) is a stable integration of two inducible reporter genes derived from the human THP-1 monocyte cell line. THP1-Dual TM The cell is characterized by the Lucia luciferase gene (a novel secreted luciferase reporter gene) under the control of the ISG54 (interferon-stimulated gene) minimal promoter in conjunction with five interferon (IFN) stimulation response elements. THP1-Dual TM The cells also express a secretory embryonic alkaline phosphatase (SEAP) reporter gene driven by an IFN-β minimal promoter, which is fused with a transcriptional response element shared by five copies of NF-KB and a c-Rel binding site in three copies. As a result, THP1-Dual TMCellular studies allow for the simultaneous investigation of the NF-κB pathway by monitoring SEAP activity and the interferon regulatory factor (IRF) pathway by assessing Lucia luciferase activity, enabling the concurrent study of two major downstream signaling pathways of STING. Both reporter proteins are readily measurable in cell culture supernatants when using QUANTI-Blue (SEAP assay) and QUANTI-Luc (Lucia luciferase assay). The NF-κB pathway is investigated by detecting SEAP activity, and the IRF pathway is investigated by assessing Lucia luciferase activity.
[0408] Add 100 μL of cell suspension (approximately 100,000 cells) to each well of a flat-bottomed 96-well plate. Then, add the reference or test compound at 20 serial dilutions in a final concentration range of 1 nM–100 μM in 0.1% DMSO / growth medium. Incubate the plates at 37°C and 5% CO2 for 24 h. Add 50 μL of THP1-Dual to each well. TM Cell culture medium was pipetted into 96-well opaque white plates. 50 μL of QUANTI-Luc assay solution was added to each well, and the plate was gently tapped several times to mix. Readings were immediately taken using TECAN. The activation level of IFN-β was positively correlated with the detected luciferin intensity. Dose-response curves were plotted using Graphpad Prism software, and the EC50 of the analyte was analyzed. 50 Merck's MSA-2 was used as the positive control in the test.
[0409] As mentioned above, THP1-Dual TM The results of the reporter gene activity assay are shown in Table 3.
[0410] Table 3 THP1-Dual TM Reporter gene activity assay results
[0411]
[0412] As shown in the table above, the STING agonist peptide conjugate of this application exhibits significantly better activity than MSA-2, indicating that it has excellent activity.
[0413] II. Experimental Study on Tumor-Targeting Activity of STING Agonist Peptide Conjugates
[0414] The breast cancer cell line 4T1 was seeded into 96-well culture plates at a cell density of 1×10⁻⁶ cells / well. 6Cells were cultured at a density of 100 μL / mL, with 4 replicates per well. 1 μM of different STING agonist peptide conjugates were added to the culture wells of the experimental groups, while an equal volume of PBS was added to the control group. After all cells were added, they were cultured at 37°C and 5% CO2 for 24 hours. Then, 10 μL of CCK8 reagent was added, and the cells were incubated at 37°C and 5% CO2 for another 2 hours. The absorbance (OD) of each well was measured using a microplate reader at 490 nm. Cell viability or proliferation activity was calculated based on the OD values. Viability or proliferation activity can be calculated using the following formula: Viability or proliferation activity = (Experimental group OD value - Blank group OD value) / (Control group OD value - Blank group OD value) * 100%.
[0415] Table 4. Survival rate or proliferative activity of breast cancer cells treated with different STING agonist peptide conjugates
[0416]
[0417] As shown in the table above, through the CCK-8 assay, we can observe that the STING agonist peptide conjugate added to this regimen significantly inhibits tumor cell proliferation and reduces cell activity compared to the positive control drug MSA-2, indicating that the STING agonist peptide conjugate has targeting activity against tumor cells.
[0418] III. Safety Testing of STING Agonist Peptide Conjugates
[0419] THP-1 cells were seeded in 96-well culture plates at a cell density of 1×10⁻⁶. 5 Cells were cultured at a density of 100 μL / mL, with 3 replicates per well. 10 μM of different STING agonist peptide conjugates were added to the culture wells of the experimental groups, while the control group received equal volumes of MSA-2 and PBS. After all cells were added, they were cultured at 37°C and 5% CO2 for 24 hours. Then, 10 μL of CCK8 reagent was added, and the cells were incubated at 37°C and 5% CO2 for another 2 hours. The absorbance (OD) of each well was measured using a microplate reader at 490 nm. Cell viability was calculated based on the OD values. Viability or proliferation activity can be calculated using the following formula: Viability or proliferation activity = (Experimental group OD value - Blank group OD value) / (Control group OD value - Blank group OD value) * 100%.
[0420] HEK293T cells were seeded in 96-well culture plates at a cell density of 1×10⁻⁶. 5Cells were cultured at a density of 100 μL / mL, with 3 replicates per well. 10 μM of different STING agonist peptide conjugates were added to the culture wells of the experimental groups, while the control group received equal volumes of MSA-2 and PBS. After all cells were added, they were cultured at 37°C and 5% CO2 for 24 hours. Then, 10 μL of CCK8 reagent was added, and the cells were incubated at 37°C and 5% CO2 for another 2 hours. The absorbance (OD) of each well was measured using a microplate reader at 490 nm. Cell viability was calculated based on the OD values. Viability or proliferation activity can be calculated using the following formula: Viability or proliferation activity = (Experimental group OD value - Blank group OD value) / (Control group OD value - Blank group OD value) * 100%.
[0421] As shown in Figure 5, compared with the positive drug MSA-2, the STING agonist peptide conjugate of this application did not significantly inhibit the proliferation of THP-1 cells and HEK293T cells in the CCK-8 assay, and the cell survival rate was high. This indicates that the STING agonist peptide conjugate has no significant effect on the growth of THP-1 and HEK293T cells and has good safety.
[0422] IV. Enzymatic release assay of STING agonist peptide conjugate
[0423] Prepare the buffer solution: 50 mM 2-(N-morpholino)ethanesulfonic acid (MES), 250 mM sodium chloride, and adjust the pH to 5.0 with 1 M sodium hydroxide solution.
[0424] Enzyme digestion activation experiment: Dissolve the test compound in buffer to prepare a 0.5 mM solution. Accurately transfer 50 μL of the test compound solution into a centrifuge tube, add 50 μL of buffer, and then add 100 μL of cathepsin B, matrix metalloproteinase-2, carboxylesterase 1, leguminase, or glutathione at a concentration of 1 mg / mL. Incubate at 37℃ for 2 h, and detect the reaction solution using liquid chromatography-mass spectrometry (LC-MS).
[0425]
[0426] In summary, the STING agonist peptide conjugate of the present invention can target the tumor microenvironment and release the STING agonist in a controlled manner at specific times and spaces, thereby increasing the drug accumulation at the tumor site, reducing drug loss during blood circulation, improving drug treatment efficiency and bioavailability, reducing toxic side effects, and achieving the goal of synergistic effect and reduced toxicity.
[0427] The STING agonist polypeptide conjugate of the present invention improves the targeting of STING agonist drugs to tumor tissues and reduces toxic side effects on normal tissues, providing a new approach for tumor immunotherapy research.
[0428] The above embodiments describe in detail the structure, features, and effects of the present invention. The above description is only a preferred embodiment of the present invention. Any changes made in accordance with the concept of the present invention, or equivalent embodiments modified to have equivalent changes, shall still fall within the scope of protection of the present invention if they do not exceed the scope covered by the specification.
Claims
1. A STING agonist polypeptide conjugate, characterized in that, The STING agonist polypeptide conjugate is one of the structures shown in (1)-(51) below: 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 。 2. A pharmaceutical composition comprising the STING agonist polypeptide conjugate of claim 1 and a pharmaceutically acceptable carrier.
3. The use of the STING agonist polypeptide conjugate of claim 1 or a pharmaceutically acceptable salt or the pharmaceutical composition of claim 2 in the preparation of a medicament for the prevention or treatment of tumors, characterized in that, The tumor is one or more of the following: gastrointestinal cancer, liver cancer, pancreatic cancer, biliary tract cancer, genitourinary system cancer, malignant mesothelioma, osteosarcoma, esophageal cancer, laryngeal cancer, lung cancer, breast cancer, hematologic cancer, brain cancer, neuroblastoma, Ewing sarcoma, skin cancer, and oral cancer.
Citation Information
Patent Citations
Multi-arm targeted anti-cancer conjugate
CN108727583A
RGD polypeptide-camptothecin polypeptide drug conjugate and application thereof
CN111068068A
Polypeptide coupling medicine of somatostatin receptor binding peptide coupling TLR agonist and preparation method of polypeptide coupling medicine
CN119792557A
Benzothiophene compound as well as pharmaceutical composition, pharmaceutical preparation and application thereof
CN119798215A
PD-L1 / TGF-beta / STING triple targeting antibody coupling drug as well as preparation method and application thereof
CN120459313A
